MeiraGTx Holdings plc 8-K

What Happened
MeiraGTx Holdings plc announced on June 30, 2026 that its subsidiary MeiraGTx, LLC entered a Royalty Note Purchase Agreement to sell senior secured royalty notes of up to $375 million in staged purchases, with an initial $100 million draw closed on June 30, 2026. The agreement was arranged with purchasers led by Maverick SA LLC (an affiliate of funds managed by Oberland Capital). The company also entered a separate securities purchase agreement on June 30, 2026 to sell 950,570 ordinary shares for roughly $10.0 million (at $10.52/share) to investors affiliated with Oberland, with a closing scheduled for July 17, 2026 and an option for up to $15.0 million more. On June 30, 2026 MeiraGTx fully redeemed and terminated its prior Perceptive notes agreement, paying principal, accrued interest and related fees.

Key Details

• Royalty facility up to $375 million in multiple Purchases: Initial Purchase $100M (closed 6/30/2026); Second Purchase $25M (7/17/2026); additional optional purchases: $50M (AQUAx2 positive data), $50M (bota‑vec marketing approval), $50M (AAV‑hAQP1 FDA approval), and a discretionary sixth Purchase up to $100M.
• Purchasers receive capped revenue payments equal to 1.95% of global net sales of Included Products (AAV‑AIPL1, AAV‑hAQP1, bota‑vec), subject to caps and adjustments tied to total purchases, voluntary repurchases, and a Test Date (Dec 31, 2031) performance metric. Revenue payments become payable quarterly after marketing approval for each product.
• Equity sale: 950,570 ordinary shares at $10.52/share (~$10.0M) closing 7/17/2026; investors have the right to buy additional shares up to $15.0M. Company agreed to file a resale registration statement by Nov 15, 2026.
• Prior debt: MeiraGTx redeemed in full its Perceptive notes on June 30, 2026; no early termination penalties were incurred. The royalty notes are secured by liens on cash, equity interests, receivables, PP&E and certain product-related assets.

Why It Matters
This transaction provides near-term liquidity (initial $100M plus ~$10M equity) and replaces the prior Perceptive debt, which may simplify the company’s capital structure. However, the royalty notes create a secured, long‑term payment obligation tied to future product sales: investors will receive a fixed percentage of net sales (capped) for the Included Products once they are commercialized. That means a portion of future revenues from these gene therapies will go to royalty investors rather than remaining wholly available to shareholders or to fund operations. The agreement also grants purchasers security interests in key assets and includes conditions that can adjust payment rates based on cumulative payments by the Dec 31, 2031 Test Date—factors investors should weigh when assessing future cash flow and upside from MeiraGTx’s product launches.